Regents of the University of California’s CytomX Therapeutics CTMX Stock Holding History

Regents of the University of California’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-37,500	Closed	-$162K	–	44
2021 Q4	$162K	Hold	37,500	–	–	0.02%	40
2021 Q3	$191K	Sell	37,500 -37,500	-50%	-$201K	0.02%	37
2021 Q2	$475K	Hold	75,000	–	–	0.06%	29
2021 Q1	$580K	Buy	+75,000	New	+$594K	0.08%	26
2017 Q3	–	Sell	-36,499	Closed	-$566K	–	22
2017 Q2	$566K	Sell	36,499 -34,085	-48%	-$514K	2.48%	14
2017 Q1	$1.22M	Buy	70,584 +22,918	+48%	+$302K	5.97%	6
2016 Q4	$524K	Sell	47,666 -23,700	-33%	-$287K	1.86%	19
2016 Q3	$1.12M	Hold	71,366	–	–	3.2%	11
2016 Q2	$729K	Buy	+71,366	New	+$814K	2.45%	16

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Regents of the University of California's CTMX Position: Q1 2022 in Review

Regents of the University of California sold out of CytomX Therapeutics (CTMX) in Q1 2022, closing a stake of 37,500 shares — an estimated $162K sold.

Regents of the University of California first reported a position in CTMX in Q2 2016 and held it in 9 quarters. The position peaked at $1.22M in Q1 2017. 119 funds tracked by Wall St. Rank hold CTMX as of Q1 2022.

Regents of the University of California reported no remaining CytomX Therapeutics position as of Q1 2022 after selling out during the quarter.
Regents of the University of California sold 37,500 CytomX Therapeutics shares in Q1 2022, an estimated $162K.
Regents of the University of California first reported a position in CytomX Therapeutics in Q2 2016 and held it in 9 quarters.
Regents of the University of California's CytomX Therapeutics position peaked at $1.22M in Q1 2017.
119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2022.

Based on Regents of the University of California's 13F filing for Q1 2022, filed 25 Apr 2022.